Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.81 |
| ▸ | NPC1 | O15118 | 7/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | WDR5 | P61964 | 2/20 | 0.52 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8442717 | 0.90 | RAB9A (0.79) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL106519 | 0.90 | RAB9A (1.00) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL30053816 | 0.90 | RAB9A (1.00) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL1680900 | 0.89 | RAB9A (0.98) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL29323856 | 0.89 | RAB9A (0.86) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL1681186 | 0.89 | RAB9A (0.98) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL6948284 | 0.89 | RAB9A (0.98) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6440543 | 0.88 | RAB9A (0.85) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL1681462 | 0.87 | RAB9A (0.90) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Water SCHEMBL6737292 | 0.87 | RAB9A (0.83) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0800385-B1 | ORAL SUSTAINED-RELEASE PREPARATION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-12-20 | — | — | EP | claimed |
| US-6113941-A | POLYMER WITH IMIDAZOLE, BENZIMIDAZOLE, TRIAZOLE AND ALANYL GLYCINE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-05 | — | — | US | claimed |
| EP-0800385-A1 | ORAL SUSTAINED-RELEASE PREPARATION | Takeda Chemical Industries, Ltd. (JP) | 1997-10-15 | — | — | EP | claimed |
| WO-1996010397-A1 | ORAL SUSTAINED-RELEASE PREPARATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-11 | — | — | WO | claimed |
| EP-0382489-B1 | Use of benzimidazole derivatives as antibacterial agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-11-17 | — | — | EP | claimed |
| US-5013743-A | Use of substituted pyridylmethylsulfinyl- and pyridylmethylthiobenzimidazoles such as lansoprazole, 2-(3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl)methylthiobenzimidazole | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-05-07 | — | — | US | claimed |
| EP-0382489-A2 | Use of benzimidazole derivatives as antibacterial agents | Takeda Chemical Industries, Ltd. (JP) | 1990-08-16 | — | — | EP | claimed |
| US-4628098-A | Including Prevacid (TM) lansoprazole, 2-(3-methyl-4-(2,2,2-trifluoroethoxy)-5-methyl-pyrid-2 -yl)methylsulfinylbenzimidazole; proton pump inhibitors, antiulcer, antisecretory agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-12-09 | — | — | US | claimed |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | disclosed |
| EP-2790696-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | Atopix Therapeutics Limited (GB) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088109-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | OXAGEN LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | SOHNSTEARNS & STERN | 2004-12-23 | — | — | US | disclosed |
| EP-0800385-B1 | ORAL SUSTAINED-RELEASE PREPARATION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-12-20 | — | — | EP | disclosed |
| US-6113941-A | POLYMER WITH IMIDAZOLE, BENZIMIDAZOLE, TRIAZOLE AND ALANYL GLYCINE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-05 | — | — | US | disclosed |
| EP-0800385-A1 | ORAL SUSTAINED-RELEASE PREPARATION | Takeda Chemical Industries, Ltd. (JP) | 1997-10-15 | — | — | EP | disclosed |
| EP-0585722-B1 | Benzimidazole derivatives as antimicrobal agent against Campylobacter pylon | EISAI CO LTD (JP) | 1996-05-15 | — | — | EP | disclosed |
| WO-1996010397-A1 | ORAL SUSTAINED-RELEASE PREPARATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
| US-5456920-A | Tablet containing active ingredient, excipient, oily or fatty substance having relatively low melting point; improved abrasion resistance | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-10 | — | — | US | disclosed |
| EP-0610854-A1 | Tablets with improved abrasion resistance and method to produce them | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-17 | — | — | EP | disclosed |
| EP-0585722-A1 | Benzimidazole derivatives as antimicrobal agent against Campylobacter pylon | Eisai Co., Ltd. (JP) | 1994-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | HRH2, HRH1, HRH4 | RAB9A 2407/4885NPC1 646/4885CYP1A2 230/4885 |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | RAB9A 561/4885NPC1 1315/4885CYP1A2 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.